Description

TEEVIR TAB (1X30)

Indications

TEEVIR TAB is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients aged 2 years and older. It is used in patients with evidence of active viral replication and liver inflammation. Additionally, TEEVIR TAB may be utilized in combination with other antiviral agents for patients with multi-drug resistant HBV strains. The primary goal of therapy is to achieve viral suppression, improve liver function, and prevent the progression of liver disease.

Mechanism of Action

TEEVIR TAB contains the active ingredient Tenofovir Alafenamide, a nucleotide reverse transcriptase inhibitor (NRTI). It works by inhibiting the reverse transcriptase enzyme, which is crucial for the replication of the hepatitis B virus. By blocking this enzyme, TEEVIR TAB prevents the conversion of viral RNA into DNA, thereby reducing the viral load in the body. This action helps to lower the risk of liver damage and complications associated with chronic hepatitis B infection.

Pharmacological Properties

TEEVIR TAB exhibits a favorable pharmacokinetic profile, characterized by its high intracellular concentrations of the active metabolite, Tenofovir diphosphate. This allows for effective viral suppression with a lower dose compared to older formulations of Tenofovir. The bioavailability of TEEVIR TAB is enhanced when taken with food, leading to improved absorption and efficacy. The drug is primarily eliminated through the kidneys, necessitating careful monitoring of renal function in patients undergoing treatment.

Contraindications

TEEVIR TAB is contraindicated in patients with a known hypersensitivity to Tenofovir Alafenamide or any of the excipients in the formulation. It should also be avoided in individuals with severe renal impairment (creatinine clearance less than 15 mL/min) or those who are on dialysis, as the drug may accumulate and lead to toxicity. Additionally, caution is advised when considering TEEVIR TAB in patients with a history of significant liver disease or those who have previously experienced lactic acidosis or severe hepatomegaly.

Side Effects

The use of TEEVIR TAB may be associated with several side effects, although many patients tolerate the medication well. Common side effects include headache, nausea, diarrhea, and fatigue. More serious adverse effects can occur, such as renal impairment, lactic acidosis, and hepatotoxicity. Patients should be monitored regularly for signs of these complications, especially during the initial stages of treatment. If any severe or unusual symptoms occur, it is essential to seek medical attention promptly.

Dosage and Administration

The recommended dosage of TEEVIR TAB for adults and pediatric patients aged 12 years and older is one tablet (25 mg) taken orally once daily, with or without food. For pediatric patients aged 2 to less than 12 years, the dosage should be determined based on body weight, and it is crucial to follow the prescribing physician’s guidance. Adherence to the prescribed regimen is vital for achieving optimal therapeutic outcomes. If a dose is missed, it should be taken as soon as remembered, but if it is close to the time of the next dose, the missed dose should be skipped. Patients should not take two doses at once.

Interactions

TEEVIR TAB may interact with other medications, which can affect its efficacy or increase the risk of adverse effects. Co-administration with other nephrotoxic agents should be approached with caution, as this may exacerbate renal toxicity. Additionally, drugs that induce or inhibit hepatic enzymes may alter the metabolism of TEEVIR TAB. It is essential for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before initiating treatment with TEEVIR TAB, a thorough medical history and assessment of renal function should be conducted. Regular monitoring of renal parameters is recommended throughout the course of therapy, particularly in patients with pre-existing renal impairment or those taking concomitant nephrotoxic medications. Patients should also be evaluated for signs of lactic acidosis and hepatotoxicity, especially during the first few months of treatment. It is advised that pregnant or breastfeeding women discuss the risks and benefits of TEEVIR TAB with their healthcare provider.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of TEEVIR TAB in managing chronic hepatitis B infection. In randomized controlled trials, patients receiving TEEVIR TAB showed significant reductions in HBV DNA levels compared to placebo. Furthermore, the drug was associated with improved liver function tests and a favorable safety profile. Long-term studies indicate that TEEVIR TAB effectively maintains viral suppression and has a low incidence of resistance, making it a valuable option in the treatment of chronic hepatitis B.

Conclusion

TEEVIR TAB (1X30) represents a significant advancement in the management of chronic hepatitis B infection. Its mechanism of action, favorable pharmacokinetic properties, and clinical efficacy make it an important therapeutic option for patients. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Regular monitoring and patient education are crucial components of successful treatment with TEEVIR TAB, ensuring that patients achieve optimal outcomes while minimizing risks.